The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 9, 2015, Pages 1887-1894

  Yang, Yang ^a,b   Hu, Wei ^a   Jiang, Shuai ^b   Wang, Bodong ^a   Li, Yue ^a   Fan, Chongxi ^a   Di, Shouyin ^a   Ma, Zhiqiang ^a   Lau, Wayne Bond ^c   Qu, Yan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Adiponectin; Cerebrovascular diseases; Neurodegenerative diseases

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG DELIVERY SYSTEM; HUMAN; HUNTINGTON CHOREA; INCIDENCE; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

EID: 84947711624     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.06.019     Document Type: Review

References (96)

1. Campbell-Taylor I. Contribution of Alzheimer disease to mortality in the United States. Neurology 2014, 83:1302.
2. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M., Howard V., Kissela B., Kittner S., Lloyd-Jones D., McDermott M., Meigs J., Moy C., Nichol G., O'Donnell C.J., Roger V., Rumsfeld J., Sorlie P., Steinberger J., Thom T., Wasserthiel-Smoller S., Hong Y. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
3. Tissue Plasminogen Activator for Acute Ischemic Stroke The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 1995, 333:1581-1587.
4. Kidwell C.S., Shephard T., Tonn S., Lawyer B., Murdock M., Koroshetz W., Alberts M., Hademenos G.J., Saver J.L. Establishment of primary stroke centers: a survey of physician attitudes and hospital resources. Neurology 2003, 60:1452-1456.
5. Fisher M. Cerebral microbleeds: where are we now?. Neurology 2014, 83:1304-1305.
6. Song T.J., Kim J., Song D., Nam H.S., Kim Y.D., Lee H.S., Heo J.H. Association of cerebral microbleeds with mortality in stroke patients having atrial fibrillation. Neurology 2014, 83:1308-1315.
7. Koivunen R.J., Satopaa J., Haapaniemi E., Strbian D., Meretoja A., Mustanoja S., Silvennoinen H., Salonen O., Niemela M., Tatlisumak T., Putaala J. Predictors of early mortality in young adults after intracerebral hemorrhage. Stroke 2014, 45:2454-2456.
8. Malec-Litwinowicz M., Rudzinska M., Szubiga M., Michalski M., Tomaszewski T., Szczudlik A. Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients. Neurol. Neurochir. Pol. 2014, 48:258-261.
9. Seelen M., Vermeulen R.C., van Dillen L.S., van der Kooi A.J., Huss A., de Visser M., van den Berg L.H., Veldink J.H. Residential exposure to extremely low frequency electromagnetic fields and the risk of ALS. Neurology 2014, 83:1767-1769.
10. Renaldi O., Pramono B., Sinorita H., Purnomo L.B., Asdie R.H., Asdie A.H. Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Med. Indones. 2009, 41:20-24.
11. Lara-Castro C., Fu Y., Chung B.H., Garvey W.T. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr. Opin. Lipidol. 2007, 18:263-270.
12. Katakami N., Kaneto H., Matsuoka T.A., Takahara M., Maeda N., Shimizu I., Ohno K., Osonoi T., Kawai K., Ishibashi F., Imamura K., Kashiwagi A., Kawamori R., Matsuhisa M., Funahashi T., Yamasaki Y., Shimomura I. Adiponectin G276T gene polymorphism is associated with cardiovascular disease in Japanese patients with type 2 diabetes. Atherosclerosis 2012, 220:437-442.
13. Vasseur F., Meyre D., Froguel P. Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert Rev. Mol. Med. 2006, 8:1-12.
14. Li Q., Lu Y., Sun L., Yan J., Yan X., Fang L., Li M., Fan Z. Plasma adiponectin levels in relation to prognosis in patients with angiographic coronary artery disease. Metabolism 2012, 61:1803-1808.
15. Qiu G., Wan R., Hu J., Mattson M.P., Spangler E., Liu S., Yau S.Y., Lee T.M., Gleichmann M., Ingram D.K., So K.F., Zou S. Adiponectin protects rat hippocampal neurons against excitotoxicity. Age (Dordr.) 2011, 33:155-165.
16. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995, 270:26746-26749.
17. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 1996, 271:10697-10703.
18. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun. 1996, 221:286-289.
19. Nakano Y., Tobe T., Choi-Miura N.H., Mazda T., Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. 1996, 120:803-812.
20. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
21. Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2004, 24:29-33.
22. Hara K., Yamauchi T., Kadowaki T. Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans. Curr. Diab. Rep. 2005, 5:136-140.
23. Ukkola O., Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities?. J. Mol. Med. (Berl.) 2002, 80:696-702.
24. Diez J.J., Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 2003, 148:293-300.
25. Nedvidkova J., Smitka K., Kopsky V., Hainer V. Adiponectin, an adipocyte-derived protein. Physiol. Res. 2005, 54:133-140.
26. Steffens S., Mach F. Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. Circ. Res. 2008, 102:140-142.
27. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J. Allergy Clin. Immunol. 2008, 121:326-330.
28. Dalamaga M., Diakopoulos K.N., Mantzoros C.S. The role of adiponectin in cancer: a review of current evidence. Endocr. Rev. 2012, 33:547-594.
29. Wang Y., Lam K.S., Xu A. Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res. 2007, 17:280-282.
30. Shapiro L., Scherer P.E. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 1998, 8:335-338.
31. Pajvani U.B., Du X., Combs T.P., Berg A.H., Rajala M.W., Schulthess T., Engel J., Brownlee M., Scherer P.E. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J. Biol. Chem. 2003, 278:9073-9085.
32. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
33. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.S., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10308-10313.
34. Tanabe H., Fujii Y., Okada-Iwabu M., Iwabu M., Nakamura Y., Hosaka T., Motoyama K., Ikeda M., Wakiyama M., Terada T., Ohsawa N., Hato M., Ogasawara S., Hino T., Murata T., Iwata S., Hirata K., Kawano Y., Yamamoto M., Kimura-Someya T., Shirouzu M., Yamauchi T., Kadowaki T., Yokoyama S. Crystal structures of the human adiponectin receptors. Nature 2015, 520:312-316.
35. Yamauchi T., Kamon J., Waki H., Imai Y., Shimozawa N., Hioki K., Uchida S., Ito Y., Takakuwa K., Matsui J., Takata M., Eto K., Terauchi Y., Komeda K., Tsunoda M., Murakami K., Ohnishi Y., Naitoh T., Yamamura K., Ueyama Y., Froguel P., Kimura S., Nagai R., Kadowaki T. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 2003, 278:2461-2468.
36. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8:1288-1295.
37. Chen M.B., McAinch A.J., Macaulay S.L., Castelli L.A., O'Brien P.E., Dixon J.B., Cameron-Smith D., Kemp B.E., Steinberg G.R. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J. Clin. Endocrinol. Metab. 2005, 90:3665-3672.
38. Kaminski T., Smolinska N., Maleszka A., Kiezun M., Dobrzyn K., Czerwinska J., Szeszko K., Nitkiewicz A. Expression of adiponectin and its receptors in the porcine hypothalamus during the oestrous cycle. Reprod. Domest. Anim. 2014, 49:378-386.
39. Kim J., Zheng W., Grafer C., Mann M.L., Halvorson L.M. GnRH decreases adiponectin expression in pituitary gonadotropes via the calcium and PKA pathways. Reprod. Sci. 2013, 20:937-945.
40. Fang X., Sweeney G. Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem. Soc. Trans. 2006, 34:798-801.
41. Bonnard C., Durand A., Vidal H., Rieusset J. Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice. Diabetes Metab. 2008, 34:52-61.
42. Shen L., Miao J., Yuan F., Zhao Y., Tang Y., Wang Y., Yang G.Y. Overexpression of adiponectin promotes focal angiogenesis in the mouse brain following middle cerebral artery occlusion. Gene Ther. 2013, 20:93-101.
43. Nishimura M., Izumiya Y., Higuchi A., Shibata R., Qiu J., Kudo C., Shin H.K., Moskowitz M.A., Ouchi N. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 2008, 117:216-223.
44. Sasaki M., Kawano T., Saito T., Yuzawa M., Ikoma A., Tamemoto H., Kawakami M., Ishikawa S.E. Hypoadiponectinemia in patients with cerebral infarction: comparison with other atherosclerotic disorders. Am. J. Med. Sci. 2007, 333:140-144.
45. Pera J., Dziedzic T., Szczudlik A., Slowik A. Temporal changes of adiponectin plasma levels in patients with acute ischemic stroke. Neurol. Res. 2013, 35:988-991.
46. Chen X.L., Cheng J.Q., Zhang R.L., Liu J.P., Li X.X., Tong Y.Q., Geng Y.J. Study on the relationship between polymorphism of adiponectin gene and risk of ischemic stroke among Han population in the Northern parts of China. Zhonghua Liu Xing Bing Xue Za Zhi 2010, 31:129-132.
47. Bang O.Y., Saver J.L., Ovbiagele B., Choi Y.J., Yoon S.R., Lee K.H. Adiponectin levels in patients with intracranial atherosclerosis. Neurology 2007, 68:1931-1937.
48. Kim B.J., Lee S.H., Ryu W.S., Kim C.K., Yoon B.W. Adipocytokines and ischemic stroke: differential associations between stroke subtypes. J. Neurol. Sci. 2012, 312:117-122.
49. Kuwashiro T., Ago T., Kamouchi M., Matsuo R., Hata J., Kuroda J., Fukuda K., Sugimori H., Fukuhara M., Awano H., Isomura T., Suzuki K., Yasaka M., Okada Y., Kiyohara Y., Kitazono T. Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS). Metabolism 2014, 63:1093-1103.
50. Efstathiou S.P., Tsioulos D.I., Tsiakou A.G., Gratsias Y.E., Pefanis A.V., Mountokalakis T.D. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005, 36:1915-1919.
51. Sasaki M., Otani T., Kawakami M., Ishikawa S.E. Elevation of plasma retinol-binding protein 4 and reduction of plasma adiponectin in subjects with cerebral infarction. Metabolism 2010, 59:527-532.
52. Chen B., Liao W.Q., Xu N., Xu H., Wen J.Y., Yu C.A., Liu X.Y., Li C.L., Zhao S.M., Campbell W. Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. Brain Res. 2009, 1273:129-137.
53. Miao J., Shen L.H., Tang Y.H., Wang Y.T., Tao M.X., Jin K.L., Zhao Y.J., Yang G.Y. Overexpression of adiponectin improves neurobehavioral outcomes after focal cerebral ischemia in aged mice. CNS Neurosci. Ther. 2013, 19:969-977.
54. Ogorodnikova A.D., Wassertheil-Smoller S., Mancuso P., Sowers M.R., Rajpathak S.N., Allison M.A., Baird A.E., Rodriguez B., Wildman R.P. High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study. Stroke 2010, 41:1376-1381.
55. Takeuchi S., Wada K., Otani N., Osada H., Nagatani K., Mori K. Temporal profile of plasma adiponectin level and delayed cerebral ischemia in patients with subarachnoid hemorrhage. J. Clin. Neurosci. 2014, 21:1007-1010.
56. Wang W.H., Yu W.H., Dong X.Q., Zhang Z.Y., Zhu Q., Che Z.H., Du Q., Wang H. Plasma adiponectin as an independent predictor of early death after acute intracerebral hemorrhage. Clin. Chim. Acta 2011, 412:1626-1631.
57. Huang Z., Yin Q., Sun W., Zhu W., Li Y., Liu W., Xiao L., Duan Z., Cai Q., Liu D., Ma M., Liu X. Microbleeds in ischemic stroke are associated with lower serum adiponectin and higher soluble E-selectin levels. J. Neurol. Sci. 2013, 334:83-87.
58. Osuka K., Watanabe Y., Yasuda M., Takayasu M. Adiponectin activates endothelial nitric oxide synthase through AMPK signaling after subarachnoid hemorrhage. Neurosci. Lett. 2012, 514:2-5.
59. Teixeira A.L., Diniz B.S., Campos A.C., Miranda A.S., Rocha N.P., Talib L.L., Gattaz W.F., Forlenza O.V. Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease. Neuromol. Med. 2013, 15:115-121.
60. Burns A., Iliffe S. Alzheimer's disease. BMJ 2009, 338:b158.
61. Une K., Takei Y.A., Tomita N., Asamura T., Ohrui T., Furukawa K., Arai H. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur. J. Neurol. 2011, 18:1006-1009.
62. Khemka V.K., Bagchi D., Bandyopadhyay K., Bir A., Chattopadhyay M., Biswas A. Altered serum levels of adipokines and insulin in probable Alzheimer's disease 2014, 41:525-533.
63. van Himbergen T.M., Beiser A.S., Ai M., Seshadri S., Otokozawa S., Au R., Thongtang N., Wolf P.A., Schaefer E.J. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. Arch. Neurol. 2012, 69:594-600.
64. Bigalke B., Schreitmuller B., Sopova K., Paul A., Stransky E., Gawaz M., Stellos K., Laske C. Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PLoS One 2011, 6:e20286.
65. Warren M.W., Hynan L.S., Weiner M.F. Lipids and adipokines as risk factors for Alzheimer's disease. J. Alzheimers Dis. 2012, 29:151-157.
66. Kurata T., Miyazaki K., Morimoto N. Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease 2013, 35:193-205.
67. Kraszula L., Jasinska A., Eusebio M., Kuna P., Glabinski A., Pietruczuk M. Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. Neurol. Neurochir. Pol. 2012, 46:22-28.
68. Musabak U., Demirkaya S., Genc G., Ilikci R.S., Odabasi Z. Serum adiponectin, TNF-alpha, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimens. Neuroimmunomodulation 2011, 18:57-66.
69. Beni A.A., Etemadifar M., Rezaei A., Farokhi M. Role of adiponectin in multiple sclerosis. Mult. Scler. Relat. Disord. 2014, 3:746.
70. Hietaharju A., Kuusisto H., Nieminen R., Vuolteenaho K., Elovaara I., Moilanen E. Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin study. Eur. J. Neurol. 2010, 17:332-334.
71. Piccio L., Cantoni C., Henderson J.G., Hawiger D., Ramsbottom M., Mikesell R., Ryu J., Hsieh C.S., Cremasco V., Haynes W., Dong L.Q., Chan L., Galimberti D., Cross A.H. Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. Eur. J. Immunol. 2013, 43:2089-2100.
72. Aziz N.A., Pijl H., Frolich M., Roelfsema F., Roos R.A. Leptin, adiponectin, and resistin secretion and diurnal rhythmicity are unaltered in Parkinson's disease. Mov. Disord. 2011, 26:760-761.
73. Cassani E., Cancello R., Cavanna F., Maestrini S., Di Blasio A.M., Liuzzi A., Pezzoli G., Barichella M. Serum adiponectin levels in advanced-stage Parkinson's disease patients. Park. Dis 2011, 2011:624764.
74. Sekiyama K., Waragai M., Akatsu H., Sugama S., Takenouchi T., Takamatsu Y., Fujita M., Sekigawa A., Rockenstein E., Inoue S., La Spada A.R., Masliah E., Hashimoto M. Disease-modifying effect of adiponectin in model of alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 2014, 1:479-489.
75. Li X., Geng J., Liu J. Adiponectin offers protection against L166P mutant DJ-1-induced neuronal cytotoxicity mediated by APPL1-dependent AMPK activation. Int. J. Neurosci. 2014, 124:350-361.
76. Jung T.W., Lee J.Y., Shim W.S., Kang E.S., Kim J.S., Ahn C.W., Lee H.C., Cha B.S. Adiponectin protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. Biochem. Biophys. Res. Commun. 2006, 343:564-570.
77. Jung T.W., Lee J.Y., Shim W.S., Kang E.S., Kim J.S., Ahn C.W., Lee H.C., Cha B.S. Adiponectin protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem. Pharmacol. 2006, 72:616-623.
78. Aziz N.A., Pijl H., Frolich M., van d. Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients 2010, 73:206-211.
79. Phan J., Hickey M.A., Zhang P., Chesselet M.F., Reue K. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 2009, 18:1006-1016.
80. Holscher C. New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases. Neural. Regen. Res. 2014, 9:1870-1873.
81. Yaghi S., Eisenberger A., Willey J.Z. Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment. JAMA Neurol. 2014, 71:1181-1185.
82. Mouchtouris N., Jabbour P.M., Starke R.M., Hasan D.M., Zanaty M., Theofanis T., Ding D., Tjoumakaris S.I., Dumont A.S., Ghobrial G.M., Kung D., Rosenwasser R.H., Chalouhi N. Biology of cerebral arteriovenous malformations with a focus on inflammation. J. Cereb. Blood Flow Metab. 2014, 35:167-175.
83. Lim S., Quon M.J., Koh K.K. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis 2014, 233:721-728.
84. Caselli C., D'Amico A., Cabiati M., Prescimone T., Del Ry S., Giannessi D. Back to the heart: the protective role of adiponectin. Pharmacol. Res. 2014, 82:9-20.
85. Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog. Cardiovasc. Dis. 2009, 52:126-140.
86. Arregui M., Buijsse B., Fritsche A., di Giuseppe R., Schulze M.B., Westphal S., Isermann B., Boeing H., Weikert C. Adiponectin and risk of stroke: prospective study and meta-analysis. Stroke 2014, 45:10-17.
87. Choudhary A.K., Rennie J., Cairns C., Borthwick G., Hughes J., Morton N.M., Kluth D., Conway B.R. Administration of heme arginate ameliorates murine type 2 diabetes independently of heme oxygenase activity. PLoS One 2013, 8:e78209.
88. Harada S., Kishimoto M., Kobayashi M., Nakamoto K., Fujita-Hamabe W., Chen H.H., Chan M.H., Tokuyama S. Honokiol suppresses the development of post-ischemic glucose intolerance and neuronal damage in mice. J. Nat. Med. 2012, 66:591-599.
89. Pardridge W.M. Drug targeting to the brain. Pharm. Res. 2007, 24:1733-1744.
90. Lichota J., Skjorringe T., Thomsen L.B., Moos T. Macromolecular drug transport into the brain using targeted therapy. J. Neurochem. 2010, 113:1-13.
91. Deng B., Gou X., Chen H., Li L., Zhong H., Xu H., Jiang F., Zhao Z., Wang Q., Xu L. Targeted delivery of neurogenin-2 protein in the treatment for cerebral ischemia-reperfusion injury. Biomaterials 2013, 34:8786-8797.
92. Tiebosch I.A., Dijkhuizen R.M., Cobelens P.M., Bouts M.J., Zwartbol R., van der Meide P.H., van den Bergh W.M. Effect of interferon-beta on neuroinflammation, brain injury and neurological outcome after experimental subarachnoid hemorrhage. Neurocrit. Care. 2013, 18:96-105.
93. Lee S., Kwak H.B. Role of adiponectin in metabolic and cardiovascular disease. J. Exerc. Rehabil. 2014, 10:54-59.
94. Anil Kumar S., Hima Kumari P., Shravan Kumar G., Mohanalatha C., Kavi Kishor P.B. Osmotin: a plant sentinel and a possible agonist of mammalian adiponectin. Front. Plant Sci. 2015, 6:163.
95. Swarbrick M.M., Havel P.J. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab. Syndr. Relat. Disord. 2008, 6:87-102.
96. Fargnoli J.L., Fung T.T., Olenczuk D.M., Chamberland J.P., Hu F.B., Mantzoros C.S. Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. Am. J. Clin. Nutr. 2008, 88:1213-1224.